ES2723098T3 - Agonistas del péptido CRHR2 y usos de los mismos - Google Patents

Agonistas del péptido CRHR2 y usos de los mismos Download PDF

Info

Publication number
ES2723098T3
ES2723098T3 ES09748922T ES09748922T ES2723098T3 ES 2723098 T3 ES2723098 T3 ES 2723098T3 ES 09748922 T ES09748922 T ES 09748922T ES 09748922 T ES09748922 T ES 09748922T ES 2723098 T3 ES2723098 T3 ES 2723098T3
Authority
ES
Spain
Prior art keywords
peptide agonists
peptide
crhr2 peptide
crhr2
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09748922T
Other languages
English (en)
Inventor
Ronald V Swanson
Nigel P Shankley
Veronica Moreno
Peter Gengo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2723098T3 publication Critical patent/ES2723098T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Un péptido que tiene actividad agonista hacia el receptor de la hormona liberadora de corticotropina tipo 2, dicho péptido tiene una secuencia de aminoácidos seleccionada del grupo que consiste de las SEQ ID NO 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 35, 36, 37, 39 , 40, y 41; o una sal o amida farmacéuticamente aceptable del mismo.
ES09748922T 2008-11-04 2009-11-04 Agonistas del péptido CRHR2 y usos de los mismos Active ES2723098T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11123308P 2008-11-04 2008-11-04
US17889009P 2009-05-15 2009-05-15
PCT/US2009/063276 WO2010053990A2 (en) 2008-11-04 2009-11-04 Crhr2 peptide agonists and uses thereof

Publications (1)

Publication Number Publication Date
ES2723098T3 true ES2723098T3 (es) 2019-08-21

Family

ID=41509080

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09748922T Active ES2723098T3 (es) 2008-11-04 2009-11-04 Agonistas del péptido CRHR2 y usos de los mismos

Country Status (20)

Country Link
US (1) US10040838B2 (es)
EP (1) EP2362881B1 (es)
JP (1) JP2012508014A (es)
KR (1) KR20110091720A (es)
CN (1) CN102272151B (es)
AU (1) AU2009313619A1 (es)
BR (1) BRPI0921640A2 (es)
CA (1) CA2742710A1 (es)
CO (1) CO6341479A2 (es)
CR (1) CR20110305A (es)
EA (1) EA201170647A1 (es)
EC (1) ECSP11011099A (es)
ES (1) ES2723098T3 (es)
IL (1) IL212685A0 (es)
MX (1) MX2011004718A (es)
NI (1) NI201100087A (es)
NZ (1) NZ592670A (es)
SG (1) SG171957A1 (es)
WO (1) WO2010053990A2 (es)
ZA (1) ZA201104160B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201170647A1 (ru) 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
CN104220098B (zh) 2012-02-14 2018-04-10 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2045175C (en) 1989-11-06 2003-03-18 Arthur I. Skoultchi Production of proteins using homologous recombination
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP3693671B2 (ja) * 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
CA2425902C (en) 2001-03-15 2017-01-03 Research Development Foundation Urocortin-iii and uses thereof
DK1389137T3 (da) 2001-05-21 2006-10-30 Injet Digital Aerosols Ltd Sammensætninger til lungelægemiddellevering af protein
US7144985B2 (en) * 2001-12-03 2006-12-05 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
CN100480267C (zh) * 2002-01-16 2009-04-22 宝洁公司 促肾上腺皮质激素释放因子2受体激动剂
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
KR100512483B1 (ko) * 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2737837T3 (es) * 2003-10-09 2020-01-16 Ambrx Inc Derivados poliméricos
US20080261863A1 (en) * 2004-06-12 2008-10-23 Bayer Pharmaceuticals Corp Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009027844A2 (en) 2007-05-25 2009-03-05 Celtic Pharma Management L.P. Crf conjugates with extended half-lives
KR20100061478A (ko) 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 세크레틴 및 임의의 유로딜라틴의 용도
EP2205748A1 (en) 2007-09-14 2010-07-14 BASF Plant Science GmbH Plants having increased yield-related traits and a method for making the same
EA201170647A1 (ru) 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
US20120277158A1 (en) 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
PL2734544T3 (pl) 2011-07-18 2021-05-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Sposoby i kompozycje do hamowania patologii związanej z poliomawirusem

Also Published As

Publication number Publication date
CR20110305A (es) 2011-11-10
NZ592670A (en) 2013-01-25
CA2742710A1 (en) 2010-05-14
ZA201104160B (en) 2012-11-28
KR20110091720A (ko) 2011-08-12
EP2362881A2 (en) 2011-09-07
CN102272151A (zh) 2011-12-07
MX2011004718A (es) 2011-07-28
CN102272151B (zh) 2014-08-20
NI201100087A (es) 2011-10-25
WO2010053990A2 (en) 2010-05-14
WO2010053990A3 (en) 2010-07-01
IL212685A0 (en) 2011-07-31
JP2012508014A (ja) 2012-04-05
EP2362881B1 (en) 2019-03-13
BRPI0921640A2 (pt) 2019-09-24
AU2009313619A1 (en) 2010-05-14
CO6341479A2 (es) 2011-11-21
US20100130424A1 (en) 2010-05-27
ECSP11011099A (es) 2011-07-29
EA201170647A1 (ru) 2011-12-30
SG171957A1 (en) 2011-07-28
US10040838B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
HRP20201353T1 (hr) Agonisti glukagonskog receptora
ES2526292T3 (es) Antagonistas de la somatostatina selectivos para receptor (SSTR2)
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
ES2723098T3 (es) Agonistas del péptido CRHR2 y usos de los mismos
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
PE20220938A1 (es) Compuestos agonistas de gipr
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
HRP20090245T1 (en) Pyy agonists and uses thereof
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
BR112015030326A2 (pt) Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
PE20121528A1 (es) Metodos para administrar agentes hipoglucemiantes de larga duracion
CO6260099A2 (es) Depsipeptidos ciclicos
CL2020003293A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
CL2012000715A1 (es) Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular.